Bioarctic rushes on the message of the study | THE BUSINESS WORLD

[ad_1]

The Bioarctic BAN2401 rocket demonstrated statistically significant and dose-dependent effects in the 18-month analysis of the Phase 2B study of 856 Alzheimer's disease patients [ad_2]
Source link